NeoGenomics Announces Medicare Coverage for RaDaR Assay for Minimal Residual Disease and Recurrence in Breast CancerAccesswire • 07/27/23
Investors Make A Bundle On 10 Stocks Others Panic Sold (Like Tesla)Investors Business Daily • 07/21/23
Press release Biocartis Group NV: Biocartis appoints George Cardoza as new CFO and Head of Service DeliveryGlobeNewsWire • 07/18/23
NeoGenomics Expands Board of Directors with Appointments of Three Independent DirectorsAccesswire • 06/29/23
NeoGenomics' RaDaR Assay for Minimal Residual Disease Receives First Commercial CoverageAccesswire • 06/15/23
NeoGenomics and German Breast Group Announce New Data Demonstrating Clinical Potential of the RaDaR MRD Assay in HR+/HER2- Breast CancerAccesswire • 06/05/23
NeoGenomics to Participate at the Goldman Sachs 44th Annual Global Healthcare ConferenceAccesswire • 06/01/23
NeoGenomics to Showcase the Transformational Impact of RaDaR(R) Assay for Molecular Residual Disease and Recurrence Monitoring at ASCOAccesswire • 05/30/23
NeoGenomics to Participate at the 22nd Annual Needham Virtual Healthcare ConferenceAccesswire • 04/11/23
NeoGenomics to Share Nine Abstracts at the American Association of Cancer Research (AACR) Annual Meeting 2023Accesswire • 04/06/23
Massive Bio and NeoGenomics Announce Collaboration to Accelerate Oncology Drug Discovery and Improve Patient CareBusiness Wire • 03/22/23
NeoGenomics Announces Commercial Availability of the RaDaR(R) Molecular Residual Disease TestAccesswire • 03/16/23
NeoGenomics Expands NGS Portfolio with Launch of Neo Comprehensive(TM) - Solid Tumor CGP and Neo Comprehensive(TM) - Myeloid Disorders CGPAccesswire • 03/13/23